CLINICAL EFFECTS AND RENOPROTECTIVE FACILITIES OF OLMESARTAN AND LERKANIDIPINEAS MONOTHERAPY AND WHEN COMBINED APPLICATION IN PATIENTS WITH ARTERIAL HYPERTENSION

The evaluation of the clinical efficacy and renoprotective effects of olmesartan and lercanidipine as monotherapy and when combined application in patients with arterial hypertension (AH) 1-2 degrees and microalbuminuria (MAU).It is established that the degree of blood pressure (BP) reduction and co...

Full description

Bibliographic Details
Main Authors:	A G Evdokimova, Yu V Ryzhova, L V Gukolenko
Format:	Article
Language:	Russian
Published:	Eco-vector 2016-03-01
Series:	Клиническая практика
Subjects:	hypertension olmesartan lercanidipine microalbuminuria nephroprotection
Online Access:	https://journals.eco-vector.com/clinpractice/article/viewFile/8082/6504

id	doaj-27e698a99d8c403fadbb86cefc1921c7
record_format	Article
spelling	doaj-27e698a99d8c403fadbb86cefc1921c72020-11-25T04:00:22ZrusEco-vectorКлиническая практика 2220-30952618-86272016-03-0171112110.17816/clinpract7111-217528CLINICAL EFFECTS AND RENOPROTECTIVE FACILITIES OF OLMESARTAN AND LERKANIDIPINEAS MONOTHERAPY AND WHEN COMBINED APPLICATION IN PATIENTS WITH ARTERIAL HYPERTENSIONA G EvdokimovaYu V RyzhovaL V GukolenkoThe evaluation of the clinical efficacy and renoprotective effects of olmesartan and lercanidipine as monotherapy and when combined application in patients with arterial hypertension (AH) 1-2 degrees and microalbuminuria (MAU).It is established that the degree of blood pressure (BP) reduction and corrective influence on diurnal BP profile were similar in groups of monotherapy with olmesartan and lercanidipine. In the group of combined application of the studied drugs target BP levels were achieved in 88% of cases in the monotherapy group and 78% (1G) and 76% (2 G).Revealed renoprotective effects of olmesartan and lercanidipine as when used in monotherapy and in combination in patients with arterial hypertension of 1-2 degrees, and MAU, revealed reliable decrease in MAU. The greatest reduction in MAU was achieved in the combination therapy group.https://journals.eco-vector.com/clinpractice/article/viewFile/8082/6504hypertensionolmesartanlercanidipinemicroalbuminurianephroprotection
collection	DOAJ
language	Russian
format	Article
sources	DOAJ
author	A G Evdokimova Yu V Ryzhova L V Gukolenko
spellingShingle	A G Evdokimova Yu V Ryzhova L V Gukolenko CLINICAL EFFECTS AND RENOPROTECTIVE FACILITIES OF OLMESARTAN AND LERKANIDIPINEAS MONOTHERAPY AND WHEN COMBINED APPLICATION IN PATIENTS WITH ARTERIAL HYPERTENSION Клиническая практика hypertension olmesartan lercanidipine microalbuminuria nephroprotection
author_facet	A G Evdokimova Yu V Ryzhova L V Gukolenko
author_sort	A G Evdokimova
title	CLINICAL EFFECTS AND RENOPROTECTIVE FACILITIES OF OLMESARTAN AND LERKANIDIPINEAS MONOTHERAPY AND WHEN COMBINED APPLICATION IN PATIENTS WITH ARTERIAL HYPERTENSION
title_short	CLINICAL EFFECTS AND RENOPROTECTIVE FACILITIES OF OLMESARTAN AND LERKANIDIPINEAS MONOTHERAPY AND WHEN COMBINED APPLICATION IN PATIENTS WITH ARTERIAL HYPERTENSION
title_full	CLINICAL EFFECTS AND RENOPROTECTIVE FACILITIES OF OLMESARTAN AND LERKANIDIPINEAS MONOTHERAPY AND WHEN COMBINED APPLICATION IN PATIENTS WITH ARTERIAL HYPERTENSION
title_fullStr	CLINICAL EFFECTS AND RENOPROTECTIVE FACILITIES OF OLMESARTAN AND LERKANIDIPINEAS MONOTHERAPY AND WHEN COMBINED APPLICATION IN PATIENTS WITH ARTERIAL HYPERTENSION
title_full_unstemmed	CLINICAL EFFECTS AND RENOPROTECTIVE FACILITIES OF OLMESARTAN AND LERKANIDIPINEAS MONOTHERAPY AND WHEN COMBINED APPLICATION IN PATIENTS WITH ARTERIAL HYPERTENSION
title_sort	clinical effects and renoprotective facilities of olmesartan and lerkanidipineas monotherapy and when combined application in patients with arterial hypertension
publisher	Eco-vector
series	Клиническая практика
issn	2220-3095 2618-8627
publishDate	2016-03-01
description	The evaluation of the clinical efficacy and renoprotective effects of olmesartan and lercanidipine as monotherapy and when combined application in patients with arterial hypertension (AH) 1-2 degrees and microalbuminuria (MAU).It is established that the degree of blood pressure (BP) reduction and corrective influence on diurnal BP profile were similar in groups of monotherapy with olmesartan and lercanidipine. In the group of combined application of the studied drugs target BP levels were achieved in 88% of cases in the monotherapy group and 78% (1G) and 76% (2 G).Revealed renoprotective effects of olmesartan and lercanidipine as when used in monotherapy and in combination in patients with arterial hypertension of 1-2 degrees, and MAU, revealed reliable decrease in MAU. The greatest reduction in MAU was achieved in the combination therapy group.
topic	hypertension olmesartan lercanidipine microalbuminuria nephroprotection
url	https://journals.eco-vector.com/clinpractice/article/viewFile/8082/6504
work_keys_str_mv	AT agevdokimova clinicaleffectsandrenoprotectivefacilitiesofolmesartanandlerkanidipineasmonotherapyandwhencombinedapplicationinpatientswitharterialhypertension AT yuvryzhova clinicaleffectsandrenoprotectivefacilitiesofolmesartanandlerkanidipineasmonotherapyandwhencombinedapplicationinpatientswitharterialhypertension AT lvgukolenko clinicaleffectsandrenoprotectivefacilitiesofolmesartanandlerkanidipineasmonotherapyandwhencombinedapplicationinpatientswitharterialhypertension
_version_	1724451137812168704

CLINICAL EFFECTS AND RENOPROTECTIVE FACILITIES OF OLMESARTAN AND LERKANIDIPINEAS MONOTHERAPY AND WHEN COMBINED APPLICATION IN PATIENTS WITH ARTERIAL HYPERTENSION

Similar Items